Vaccine types

Covid-19 breakthrough infections in vaccinated people

n=30

No  Covid-19 breakthrough infections in vaccinated people

n=1970

Statistical significance

Relative risk (RR)

BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech)

18 (60)

1362 (69)

X² = 1.1533

P = 0.28285. NS

RR = 0.67 (CI 95%: 1.63, 0.27). True benefits

mRNA-1273 vaccine (Spikevax, formerly COVID-19 Vaccine Moderna)

1 (3)

259 (13)

X² with Yates correction = 1.7235. p =  0.189248. NS

RR = 0.23 (CI 95%: 2.07, 0.03). Protection factor effectively

ChAdOx1 nCoV-19 vaccine (Vaxzevria, Oxford/AstraZeneca)

6 (20)

254 (13)

X² = with Yates correction = 0.766. p = 0.381462. NS

RR = 1.67 (CI 95%: 0.53, 5.23). Moderate risk

Janssen vaccine (Johnson & Johnson vaccine)

5 (17)

95 (5)

Fisher exact test = 0.0148. Significant at p < 0.05.

RR = 3.79 (CI 95%: 1.35, 10.64). Strong risk

TOTAL

30 (100)

2000 (100)

-

-